Aarkstore. 2010. Hemophilia—Pipeline Assessment and Market Forecasts to 2017. 31Dec.2010. www.aarkstore.com/reports/Hemophilia-Pipeline-Assessment-and-Market-Forecasts-to-2017-92008.html(accessed on 1/4/12).
2.
BainbridgeJ.W., SmithA.J., BarkerS.S.et al.2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med., 358:2231–2239.
3.
BowerJ.L., ChristensenC.M.1995. Disruptive technologies—catching the wave. Harvard Business Rev., 73:43–53.
4.
CartierN., Hacein-Bey-AbinaS., BartholomaeC.C.et al.2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326:818–823.
5.
ChristensenC.M.1997. The Innovator's Dilemma. Harvard Business School Press: Boston, MA.
6.
ChristensenC.M., RaynorM.E.2003. The Innovator's Solution. Harvard Business School Press: Boston, MA.
7.
CideciyanA.V., HauswirthW.W., AlemanT.S.et al.2009. Human RPE65 gene therapy for Leber congenital amaurosis: Persistence of early visual improvements and safety at 1 year. Hum. Gene Ther., 20:999–1004.
8.
Enzon Pharmaceuticals. 2009. 2009 Form 10-K Annual Report. United States Securities and Exchange Commission: Washington, D.C., 41.
9.
FriedrichO.1983. The computer moves in. Time, January3, 1983; 21.
10.
Gartner. 2006. Gartner Says Worldwide PC Shipment Growth to Slow in 2006 STAMFORD, Conn.March9, 2006. www.gartner.com/press_releases/asset_146531_11.html(accessed 01/05/12).
11.
GasparH.B., CoorayS., GilmourK.C.et al.2011. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med., 3:97ra80.
12.
Hacein-Bey-AbinaS., HauerJ., LimA.et al.2010. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 363:355–364.
13.
MaguireA.M., SimonelliF., PierceE.A.et al.2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358:2240–2248.
14.
Manco-Johnsonet al. 2007. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N. Engl. J. Med., 357:535–544.
15.
NathwaniA.C., TuddenhamE.G., RangarajanS.et al.2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365:2357–2365.
16.
WoodcockJ.2011. PDUFA V: Medical Innovations, Jobs, and Patients. Statement of Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services before the Subcommittee on Health, Committee on Energy and Commerce, U.S. House of Representatives. July7, 2011. www.fda.gov/NewsEvents/Testimony/ucm261396.htm
